# US 2004/0073012 A1 · Antibodies specific for a cell surface molecule mediating cell adhesion and signal transmission, cells secreting such antibodies, and methods of making and using such antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0073012 A1
- Document ID: US20040073012A1
- Status: Published application
- Kind: A1
- Application number: 10/704,426
- Filed: 2003-11-07
- Published: 2004-04-15
- Earliest claimed: 1997-02-27
- Assignees: Japan Tobacco Inc., a Japanese corporation
- Inventors: Takuya Tamatani; Katsunari Tezuka
- Web page: https://patentgrep.com/patent/US20040073012A1

## CPC

- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70521: {CD28, CD152}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

## Claims

### Claim 1

A purified antibody that binds to a polypeptide consisting of SEQ ID NO:2, wherein the antibody is a human, mouse, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is monoclonal.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody is polyclonal.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody is a human, mouse or rat antibody.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is chimeric.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody is humanized.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody is a human antibody.

### Claim 9 (depends on 2)

The antibody of claim 2, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 10 (depends on 2)

The antibody of claim 2, wherein the antibody is a human, mouse or rat antibody.

### Claim 11 (depends on 2)

The antibody of claim 2, wherein the antibody is chimeric.

### Claim 12 (depends on 2)

The antibody of claim 2, wherein the antibody is humanized.

### Claim 13 (depends on 2)

The antibody of claim 2, wherein the antibody is a human antibody.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 2)

A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 3)

A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 4)

A pharmaceutical composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 5)

A pharmaceutical composition comprising the antibody of claim 5 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 6)

A pharmaceutical composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 7)

A pharmaceutical composition comprising the antibody of claim 7 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 8)

A pharmaceutical composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 9)

A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 10)

A pharmaceutical composition comprising the antibody of claim 10 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 11)

A pharmaceutical composition comprising the antibody of claim 11 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 12)

A pharmaceutical composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 13)

A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 14)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 14.

### Claim 28 (depends on 15)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 15.

### Claim 29 (depends on 16)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16.

### Claim 30 (depends on 17)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 17.

### Claim 31 (depends on 18)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 18.

### Claim 32 (depends on 19)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 19.

### Claim 33 (depends on 20)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 20.

### Claim 34 (depends on 21)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 21.

### Claim 35 (depends on 22)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 22.

### Claim 36 (depends on 23)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 23.

### Claim 37 (depends on 24)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 24.

### Claim 38 (depends on 25)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 25.

### Claim 39 (depends on 26)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 26.

### Claim 40 (depends on 14)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 14.

### Claim 41 (depends on 15)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 15.

### Claim 42 (depends on 16)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16.

### Claim 43 (depends on 17)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 17.

### Claim 44 (depends on 18)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 18.

### Claim 45 (depends on 19)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 19.

### Claim 46 (depends on 20)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 20.

### Claim 47 (depends on 21)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 21.

### Claim 48 (depends on 22)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 22.

### Claim 49 (depends on 23)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 23.

### Claim 50 (depends on 24)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 24.

### Claim 51 (depends on 25)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 25.

### Claim 52 (depends on 26)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 26.

### Claim 53 (depends on 2)

An isolated cell that produces the antibody of claim 2.

### Claim 54 (depends on 4)

An isolated cell that produces the antibody of claim 4.

### Claim 55 (depends on 5)

An isolated cell that produces the antibody of claim 5.

### Claim 56 (depends on 6)

An isolated cell that produces the antibody of claim 6.

### Claim 57 (depends on 7)

An isolated cell that produces the antibody of claim 7.

### Claim 58 (depends on 8)

An isolated cell that produces the antibody of claim 8.

### Claim 59 (depends on 9)

An isolated cell that produces the antibody of claim 9.

### Claim 60 (depends on 10)

An isolated cell that produces the antibody of claim 10.

### Claim 61 (depends on 11)

An isolated cell that produces the antibody of claim 11.

### Claim 62 (depends on 12)

An isolated cell that produces the antibody of claim 12.

### Claim 63 (depends on 13)

An isolated cell that produces the antibody of claim 13.

### Claim 64

A purified chimeric, humanized or human monoclonal antibody that binds to a polypeptide consisting of SEQ ID NO:2.

### Claim 65 (depends on 64)

The antibody of claim 64, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 66 (depends on 64)

The antibody of claim 64, wherein the antibody is chimeric.

### Claim 67 (depends on 64)

The antibody of claim 64, wherein the antibody is humanized.

### Claim 68 (depends on 64)

The antibody of claim 64, wherein the antibody is a human antibody.

### Claim 69 (depends on 64)

A pharmaceutical composition comprising the antibody of claim 64 and a pharmaceutically acceptable carrier.

### Claim 70 (depends on 65)

A pharmaceutical composition comprising the antibody of claim 65 and a pharmaceutically acceptable carrier.

### Claim 71 (depends on 66)

A pharmaceutical composition comprising the antibody of claim 66 and a pharmaceutically acceptable carrier.

### Claim 72 (depends on 67)

A pharmaceutical composition comprising the antibody of claim 67 and a pharmaceutically acceptable carrier.

### Claim 73 (depends on 68)

A pharmaceutical composition comprising the antibody of claim 68 and a pharmaceutically acceptable carrier.

### Claim 74 (depends on 69)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 69.

### Claim 75 (depends on 70)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 70.

### Claim 76 (depends on 71)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 71.

### Claim 77 (depends on 72)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 72.

### Claim 78 (depends on 73)

A method of inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 73.

### Claim 79 (depends on 69)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 69.

### Claim 80 (depends on 70)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 70.

### Claim 81 (depends on 71)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 71.

### Claim 82 (depends on 72)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 72.

### Claim 83 (depends on 73)

A method of treating glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 73.

### Claim 84 (depends on 64)

An isolated cell that produces the antibody of claim 64.

### Claim 85 (depends on 65)

An isolated cell that produces the antibody of claim 65.

### Claim 86 (depends on 66)

An isolated cell that produces the antibody of claim 66.

### Claim 87 (depends on 67)

An isolated cell that produces the antibody of claim 67.

### Claim 88 (depends on 68)

An isolated cell that produces the antibody of claim 68.

### Claim 89

A purified chimeric, humanized or human monoclonal antibody that binds to a polypeptide consisting of SEQ ID NO:13.

### Claim 90 (depends on 89)

The antibody of claim 89, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 91 (depends on 89)

The antibody of claim 89, wherein the antibody is chimeric.

### Claim 92 (depends on 89)

The antibody of claim 89, wherein the antibody is humanized.

### Claim 93 (depends on 89)

The antibody of claim 89, wherein the antibody is a human antibody.

### Claim 94 (depends on 89)

A pharmaceutical composition comprising the antibody of claim 89 and a pharmaceutically acceptable carrier.

### Claim 95 (depends on 90)

A pharmaceutical composition comprising the antibody of claim 90 and a pharmaceutically acceptable carrier.

### Claim 96 (depends on 91)

A pharmaceutical composition comprising the antibody of claim 91 and a pharmaceutically acceptable carrier.

### Claim 97 (depends on 92)

A pharmaceutical composition comprising the antibody of claim 92 and a pharmaceutically acceptable carrier.

### Claim 98 (depends on 93)

A pharmaceutical composition comprising the antibody of claim 93 and a pharmaceutically acceptable carrier.

### Claim 99 (depends on 89)

An isolated cell that produces the antibody of claim 89.

### Claim 100 (depends on 90)

An isolated cell that produces the antibody of claim 90.

### Claim 101 (depends on 91)

An isolated cell that produces the antibody of claim 91.

### Claim 102 (depends on 92)

An isolated cell that produces the antibody of claim 92.

### Claim 103 (depends on 93)

An isolated cell that produces the antibody of claim 93.

### Claim 104

A purified antibody that binds to a polypeptide consisting of SEQ ID NO:14, wherein the antibody is a human, rat, guinea pig, rabbit, dog, cat, pig, goat, horse or cow antibody.

### Claim 105 (depends on 104)

The antibody of claim 104, wherein the antibody is monoclonal.

### Claim 106 (depends on 104)

The antibody of claim 104, wherein the antibody is polyclonal.

### Claim 107 (depends on 104)

The antibody of claim 104, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 108 (depends on 104)

The antibody of claim 104, wherein the antibody is a human, rat or guinea pig antibody.

### Claim 109 (depends on 104)

The antibody of claim 104, wherein the antibody is chimeric.

### Claim 110 (depends on 104)

The antibody of claim 104, wherein the antibody is humanized.

### Claim 111 (depends on 104)

The antibody of claim 104, wherein the antibody is a human antibody.

### Claim 112 (depends on 105)

The antibody of claim 105, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 113 (depends on 105)

The antibody of claim 105, wherein the antibody is a human, rat or guinea pig antibody.

### Claim 114 (depends on 105)

The antibody of claim 105, wherein the antibody is chimeric.

### Claim 115 (depends on 105)

The antibody of claim 105, wherein the antibody is humanized.

### Claim 116 (depends on 105)

The antibody of claim 105, wherein the antibody is a human antibody.

### Claim 117 (depends on 104)

A pharmaceutical composition comprising the antibody of claim 104 and a pharmaceutically acceptable carrier.

### Claim 118 (depends on 105)

A pharmaceutical composition comprising the antibody of claim 105 and a pharmaceutically acceptable carrier.

### Claim 119 (depends on 106)

A pharmaceutical composition comprising the antibody of claim 106 and a pharmaceutically acceptable carrier.

### Claim 120 (depends on 107)

A pharmaceutical composition comprising the antibody of claim 107 and a pharmaceutically acceptable carrier.

### Claim 121 (depends on 108)

A pharmaceutical composition comprising the antibody of claim 108 and a pharmaceutically acceptable carrier.

### Claim 122 (depends on 109)

A pharmaceutical composition comprising the antibody of claim 109 and a pharmaceutically acceptable carrier.

### Claim 123 (depends on 110)

A pharmaceutical composition comprising the antibody of claim 110 and a pharmaceutically acceptable carrier.

### Claim 124 (depends on 111)

A pharmaceutical composition comprising the antibody of claim 111 and a pharmaceutically acceptable carrier.

### Claim 125 (depends on 112)

A pharmaceutical composition comprising the antibody of claim 112 and a pharmaceutically acceptable carrier.

### Claim 126 (depends on 113)

A pharmaceutical composition comprising the antibody of claim 113 and a pharmaceutically acceptable carrier.

### Claim 127 (depends on 114)

A pharmaceutical composition comprising the antibody of claim 114 and a pharmaceutically acceptable carrier.

### Claim 128 (depends on 115)

A pharmaceutical composition comprising the antibody of claim 115 and a pharmaceutically acceptable carrier.

### Claim 129 (depends on 116)

A pharmaceutical composition comprising the antibody of claim 116 and a pharmaceutically acceptable carrier.

### Claim 130 (depends on 105)

An isolated cell that produces the antibody of claim 105.

### Claim 131 (depends on 107)

An isolated cell that produces the antibody of claim 107.

### Claim 132 (depends on 108)

An isolated cell that produces the antibody of claim 108.

### Claim 133 (depends on 109)

An isolated cell that produces the antibody of claim 109.

### Claim 134 (depends on 110)

An isolated cell that produces the antibody of claim 110.

### Claim 135 (depends on 111)

An isolated cell that produces the antibody of claim 111.

### Claim 136 (depends on 112)

An isolated cell that produces the antibody of claim 112.

### Claim 137 (depends on 113)

An isolated cell that produces the antibody of claim 113.

### Claim 138 (depends on 114)

An isolated cell that produces the antibody of claim 114.

### Claim 139 (depends on 115)

An isolated cell that produces the antibody of claim 115.

### Claim 140 (depends on 116)

An isolated cell that produces the antibody of claim 116.

### Claim 141

A purified chimeric, humanized or human monoclonal antibody that binds to a polypeptide consisting of SEQ ID NO:14.

### Claim 142 (depends on 141)

The antibody of claim 141, wherein the antibody binds to the extracellular region of the polypeptide.

### Claim 143 (depends on 141)

The antibody of claim 141, wherein the antibody is chimeric.

### Claim 144 (depends on 141)

The antibody of claim 141, wherein the antibody is humanized.

### Claim 145 (depends on 141)

The antibody of claim 141, wherein the antibody is a human antibody.

### Claim 146 (depends on 141)

A pharmaceutical composition comprising the antibody of claim 141 and a pharmaceutically acceptable carrier.

### Claim 147 (depends on 142)

A pharmaceutical composition comprising the antibody of claim 142 and a pharmaceutically acceptable carrier.

### Claim 148 (depends on 143)

A pharmaceutical composition comprising the antibody of claim 143 and a pharmaceutically acceptable carrier.

### Claim 149 (depends on 144)

A pharmaceutical composition comprising the antibody of claim 144 and a pharmaceutically acceptable carrier.

### Claim 150 (depends on 145)

A pharmaceutical composition comprising the antibody of claim 145 and a pharmaceutically acceptable carrier.

### Claim 151 (depends on 141)

An isolated cell that produces the antibody of claim 141.

### Claim 152 (depends on 142)

An isolated cell that produces the antibody of claim 142.

### Claim 153 (depends on 143)

An isolated cell that produces the antibody of claim 143.

### Claim 154 (depends on 144)

An isolated cell that produces the antibody of claim 144.

### Claim 155 (depends on 145)

An isolated cell that produces the antibody of claim 145.
